Program-wide review and follow-up of erythema Induratum of Bazin and tuberculosis-associated ocular inflammation management in a TB low-incidence setting: need for improved treatment candidate selection, therapy standardization, and care collaboration

Table 1 Demographics and case characteristics of EIB and TB-AOI cases - Alberta, 2004–14

	EIB (n = 22)	TB-AOI (n = 20)
Female gender – no. (%)	17 (77)	11 (55)
Age – years
Median (IQR)	43 (8.3)	38 (17.8)
Country of origin – no. (%)
TB-HBC*	18 (82)	14 (70)
History of latent TB^†− no. (%)	4 (18)	4 (20)
Duration of Symptoms – months (years)	n = 19	n = 15
Median	24 (2)	9 (0.8)
IQR	30 (2.5)	13 (1.1)
Diagnostics^‡
TST	n = 16	n = 16
Range - induration (mm)	10–30	12–40
Median (IQR)	18 (7)	17.5 (7.8)
IGRA	n = 13 (7 had TST)	n = 15 (11 had TST)
Positive result – no. (%)	12 (92)	13 (87)
Chest X-ray	n = 22	n = 20
TB changes^§ – no. (%)	4 (18)	1 (5)
Tissue Biopsy Pathology^#	n = 17
Granulomatous inflammation	15 (88)	No samples obtained for
Necrobiosis	9 (53)	pathology
Panniculitis	10 (59)
Vasculitis	8 (47)

*TB-HBC = TB High Burden Country as per WHO classification [40]
^†TB history = reported prior exposure, documented TST conversion (positive after a prior negative), or prior LTBI therapy
^‡TST = tuberculin skin test, IGRA = interferon-gamma release assay (QuantiFERON-TB Gold In-Tube Test)
^§TB changes (no.) = upper lobe calcification (2), multilobar ‘infiltrate’ (1), nodule (1), hilar lymphadenopathy (1)
Pathology sums to > 100% as multiple patterns present in some specimens, No AFB or organisms seen in any samples

ISSN: 1471-2334